CardioVax

From Cardiovax founded by Oye Olukotun:

The role of immune responses in atherosclerosis has been the focus of increasing scientific investigation. It is now understood that the initiation and progression of atherosclerosis is modulated by the balance between opposing immune responses, i.e, athero-protecting and athero-promoting. CardioVax’ lead product (CVX-210-H) has been formulated to blunt the athero-promoting responses and to heighten the athero-protecting responses. In the well established animal model, CVX-210-H has been shown to reduce the progression of atherosclerosis by more than 60% in treated animals versus untreated animal